Company Overview

Teva Pharmaceutical Industries Limited is a global pharmaceutical company primarily engaged in the development, manufacturing, and commercialization of generic medicines, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The company operates at scale across the pharmaceuticals industry, with revenue historically driven by its global generics portfolio and a smaller but strategically important specialty medicines segment. Teva serves healthcare systems, hospitals, pharmacies, wholesalers, and governments, with products spanning central nervous system disorders, respiratory diseases, oncology, pain management, and infectious diseases.

Founded in 1901 in Jerusalem, Teva evolved from a regional drug distributor into one of the world’s largest generic drug manufacturers through decades of organic growth and acquisitions. Its expansion accelerated in the late 20th and early 21st centuries, particularly through the acquisitions of Ivax Corporation, Barr Pharmaceuticals, and Actavis Generics (from Allergan), which significantly expanded Teva’s global footprint and product breadth. The company’s strategic positioning has since shifted toward stabilizing its generics business, reducing leverage, and refocusing on innovative specialty therapies.

Business Operations

Teva reports operations primarily through two major business segments: Generics and Specialty Medicines, with an additional focus on Active Pharmaceutical Ingredients (APIs) that supports both internal production and third-party sales. The Generics segment represents the largest share of revenue and includes a broad portfolio of off-patent medicines distributed across multiple dosage forms and therapeutic categories. The Specialty Medicines segment focuses on branded products, historically led by treatments in neurology, migraine, respiratory, and movement disorders.

The company maintains vertically integrated capabilities, including research and development, large-scale manufacturing, and global distribution. Teva operates a worldwide manufacturing network and owns proprietary formulation technologies and complex generics expertise. Its operations span both domestic and international markets, with substantial exposure to North America, Europe, and International Markets. Teva conducts business through numerous wholly owned subsidiaries and has historically engaged in supply agreements and commercialization partnerships to extend market reach.

Strategic Position & Investments

Teva’s strategic direction centers on strengthening its core generics platform while selectively investing in differentiated and innovative specialty products. Key growth initiatives include advancing complex generics, biosimilar development, and next-generation drug delivery systems, alongside lifecycle management of its specialty portfolio. The company has prioritized debt reduction and operational efficiency following prior large-scale acquisitions, while reallocating capital toward research programs with higher return potential.

Major historical acquisitions, including Actavis Generics, reshaped Teva’s scale and competitive position, though they also increased financial leverage and integration complexity. More recently, strategic investments have focused on innovation partnerships, digital health-enabled patient support programs, and pipeline assets in neuroscience and immunology. Teva also continues to invest in emerging pharmaceutical technologies where it can leverage its manufacturing scale and regulatory expertise.

Geographic Footprint

Teva operates globally, with corporate headquarters in Israel and significant operational hubs in North America and Europe. The United States represents its single largest market by revenue, particularly for generics and specialty products, while Europe contributes through both branded generics and local market portfolios across multiple countries.

Beyond these core regions, Teva maintains a presence in Latin America, Asia-Pacific, and parts of Eastern Europe, supplying medicines to both developed and emerging healthcare systems. Its extensive international manufacturing and distribution network enables broad geographic reach and supports its role as a key supplier of essential medicines worldwide.

Leadership & Governance

Teva is led by an executive team focused on operational discipline, financial stability, and long-term value creation through sustainable pharmaceutical innovation. The leadership emphasizes patient access, regulatory compliance, and responsible corporate governance, while steering the company through a complex global regulatory and competitive environment.

Key executives include:

• Richard D. Francis – President and Chief Executive Officer
• Eyal Desheh – Executive Vice President and Chief Financial Officer
• Eric Drapé – Executive Vice President, Global Operations
• Brendan O’Grady – Executive Vice President, North America Commercial
• Aimee Lenar – Executive Vice President, Global Human Resources
• Kare Schultz – Former President and Chief Executive Officer (instrumental in restructuring and debt reduction strategy)